Zacks Research Upgrades IceCure Medical (NASDAQ:ICCM) to Hold

IceCure Medical (NASDAQ:ICCM) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday, Zacks reports.

Several other analysts have also recently weighed in on ICCM. Wall Street Zen cut IceCure Medical from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, IceCure Medical has an average rating of “Hold” and a consensus price target of $30.00.

IceCure Medical Stock Up 1.9%

NASDAQ:ICCM opened at $1.10 on Monday. The company has a 50-day moving average price of $2.15 and a 200-day moving average price of $4.86. IceCure Medical has a 12 month low of $1.03 and a 12 month high of $26.97.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($1.60) earnings per share (EPS) for the quarter. IceCure Medical had a negative net margin of 427.67% and a negative return on equity of 174.26%. The company had revenue of $0.91 million for the quarter. Research analysts forecast that IceCure Medical will post -4.61 earnings per share for the current year.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is an Israel-based medical technology company that develops minimally invasive cryoablation systems for the treatment of tumors. Its technology uses liquid nitrogen to freeze and destroy targeted tissue, with the goal of providing an alternative to surgical removal in selected patients.

The company’s primary product is the ProSense system, which is designed to deliver controlled cryoablation through a probe inserted into a tumor. IceCure has focused on applications in breast, kidney, lung, and other solid tumors, including procedures performed under image guidance.